Other markers of aggressive variants of PCa such as those associated with neuroendocrine differentiation (PTEN, p53, BRCA2) could be compared with PSMA expression in patients with advanced disease with poor prognostic features or in those with visceral metastases to have a better overall picture of the biological and clinical impact of PSMA expression27–29. The gene discussed is BRCA2; the disease is posterior cortical atrophy.